Building the Companies Behind Tomorrow's Medicines
Omnium Global is a life sciences venture studio that identifies, invests in and builds biotechnology companies. We partner with exceptional founders to transform promising science into scalable businesses, strategic partnerships and products that improve patients' lives.
Partner With Us
_
Too many breakthrough technologies never reach patients. Not because the science failed, but because the company failed before the science had the chance to succeed.
OUR PURPOSE
Better Science Deserves Better Execution
The world does not need more biotechnology companies.
It needs more biotechnology companies that succeed.
Every year, remarkable scientific discoveries fail to reach patients because early-stage companies run out of capital, underestimate manufacturing, pursue inefficient development strategies or lack the experienced leadership needed to navigate the path from discovery to commercialization.
We founded Omnium Global because we believe these outcomes are not inevitable.
Our mission is to help exceptional science become exceptional companies, creating value for founders, investors and, most importantly, patients.
We measure success not only by financial returns, but by the number of technologies that ultimately improve healthcare around the world.
_
OUR INVESTMENT THESIS
We Invest Where We Can Change the Outcome
We believe breakthrough science deserves more than capital.
It deserves experienced partners who understand how great biotechnology companies are built.
We invest selectively in companies where our scientific, operational and commercial experience can fundamentally change the trajectory of the business. Capital is only the beginning. We work alongside founders through the scientific, manufacturing, regulatory and strategic decisions that determine whether breakthrough ideas become successful products and enduring companies.
We are particularly interested in companies developing:
-
Novel therapeutics
-
Drug delivery technologies
-
Platform technologies
-
Advanced biomanufacturing
-
Capital-efficient regulatory strategies, including 505(b)(2), where appropriate
-
Technologies that improve access, affordability and scalability of healthcare worldwide
_
HOW WE PARTNER
Every Company Is Different. Our Philosophy Is Not.
We start with the science.
We look for technologies capable of transforming patient care, advancing biomanufacturing or solving meaningful healthcare challenges.
We invest with conviction.
We deliberately maintain a concentrated portfolio, investing in a small number of companies where we believe our involvement can create exceptional long-term value.
We build alongside founders.
We become active partners, helping companies navigate scientific development, manufacturing, regulatory strategy, financing and business development as they grow.
We focus on outcomes.
Success is not measured by the next financing round alone. We aim to build companies capable of delivering meaningful products, attracting strategic partners and creating lasting impact.
_
WHAT WE LOOK FOR
The Companies We Back
We seek founders tackling important problems with differentiated science and ambitious visions.
We are particularly drawn to opportunities that:
-
Address significant unmet medical needs.
-
Improve patient outcomes through differentiated science.
-
Simplify, accelerate or reduce the cost of developing and manufacturing innovative medicines.
-
Leverage capital-efficient development pathways, including 505(b)(2), where appropriate.
-
Enable broader access to healthcare through scalable technologies, manufacturing innovation or lower cost of goods.
-
Have the potential to create meaningful impact for patients worldwide, including in underserved and resource-limited settings.
-
Value long-term partnerships built on trust, execution and shared ambition.
_
PORTFOLIO
Selected Portfolio Companies
Omnium Global follows a concentrated investment strategy, partnering with a small number of biotechnology companies where we believe our combination of investment, experience and execution can create meaningful long-term value.
_
WHY OMNIUM
Beyond Capital
Capital helps companies start.
Execution determines whether they succeed.
Our leadership team has spent decades building biotechnology companies, developing manufacturing strategies, leading CMC programs, negotiating strategic transactions and bringing innovative technologies closer to patients.
We believe better execution creates stronger companies, more efficient development and ultimately greater impact for patients and investors alike.
_
Leadership Team
Innovative - Pragmatic - Collaborative
Omnium Global is led by experienced biotechnology executives who have spent their careers building products, companies and strategic partnerships across the global life sciences industry. Our leadership combines scientific, operational, commercial and transaction experience developed across multinational pharmaceutical companies, emerging biotechnology ventures and successful exits.
_
OUR BELIEFS
What We Believe
We believe exceptional science deserves exceptional execution.
We believe manufacturing strategy should begin long before commercialization.
We believe capital should accelerate value creation, not simply extend runway.
We believe biotechnology innovation should improve healthcare for patients everywhere, not only those with access to the world's wealthiest healthcare systems.
We believe that expanding access to medicines through smarter development, better manufacturing and more efficient commercialization can improve millions of lives.
Above all, we believe too many transformative technologies never reach the patients who need them.
Our purpose is to help change that.
_
CONTACTS
Building Something That Matters?
If you are developing a technology with the potential to transform healthcare and are looking for a long-term investment partner, we would welcome the opportunity to start a conversation.